203 related articles for article (PubMed ID: 24453992)
1. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma.
Kikuchi K; Hettmer S; Aslam MI; Michalek JE; Laub W; Wilky BA; Loeb DM; Rubin BP; Wagers AJ; Keller C
PLoS Genet; 2014 Jan; 10(1):e1004107. PubMed ID: 24453992
[TBL] [Abstract][Full Text] [Related]
2. PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells.
Yoshida H; Miyachi M; Sakamoto K; Ouchi K; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Imamura T; Iehara T; Kakazu N; Hojo H; Hosoi H
Oncogene; 2014 Dec; 33(49):5601-8. PubMed ID: 24213582
[TBL] [Abstract][Full Text] [Related]
3. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
Schmitt-Ney M; Camussi G
PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
[TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
5. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.
Lacey A; Rodrigues-Hoffman A; Safe S
Cancer Res; 2017 Feb; 77(3):732-741. PubMed ID: 27864345
[TBL] [Abstract][Full Text] [Related]
6. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.
Nishijo K; Chen QR; Zhang L; McCleish AT; Rodriguez A; Cho MJ; Prajapati SI; Gelfond JA; Chisholm GB; Michalek JE; Aronow BJ; Barr FG; Randall RL; Ladanyi M; Qualman SJ; Rubin BP; LeGallo RD; Wang C; Khan J; Keller C
Cancer Res; 2009 Apr; 69(7):2902-11. PubMed ID: 19339268
[TBL] [Abstract][Full Text] [Related]
7. PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Linardic CM
Cancer Lett; 2008 Oct; 270(1):10-8. PubMed ID: 18457914
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
Hu Q; Yuan Y; Wang C
PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156
[TBL] [Abstract][Full Text] [Related]
9. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
[TBL] [Abstract][Full Text] [Related]
10. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
[TBL] [Abstract][Full Text] [Related]
11. Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.
Herrero Martín D; Boro A; Schäfer BW
PLoS One; 2013; 8(1):e55072. PubMed ID: 23372815
[TBL] [Abstract][Full Text] [Related]
12. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
13. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case.
Gordon A; McManus A; Anderson J; Fisher C; Abe S; Nojima T; Pritchard-Jones K; Shipley J
Cancer Genet Cytogenet; 2003 Jan; 140(1):73-7. PubMed ID: 12550764
[TBL] [Abstract][Full Text] [Related]
15. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
[TBL] [Abstract][Full Text] [Related]
16. Uncovering metabolism in rhabdomyosarcoma.
Monti E; Fanzani A
Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235
[TBL] [Abstract][Full Text] [Related]
17. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.
Kahsay A; Rodriguez-Marquez E; López-Pérez A; Hörnblad A; von Hofsten J
Sci Rep; 2022 Oct; 12(1):17149. PubMed ID: 36229514
[TBL] [Abstract][Full Text] [Related]
18. P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness.
Thuault S; Hayashi S; Lagirand-Cantaloube J; Plutoni C; Comunale F; Delattre O; Relaix F; Gauthier-Rouvière C
Oncogene; 2013 Apr; 32(15):1876-87. PubMed ID: 22710718
[TBL] [Abstract][Full Text] [Related]
19. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
20. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
